2025-01-15 - Analysis Report
## Merck & Co Inc (MRK) Stock Report

**1. Performance Comparison and Divergence:**

Merck & Co Inc (MRK) is a leading pharmaceutical company known for its innovative medicines and vaccines.

The cumulative return for MRK is 64.51%, while the S&P 500 (VOO) shows a cumulative return of 112.74%.  This represents a difference of -48.2 percentage points.  The provided relative divergence of -13.9% indicates MRK's performance is significantly below the S&P 500,  placing it in the lower 13.9% percentile of its historical performance range relative to the S&P 500.  The provided Alpha consistently shows negative values, indicating underperformance relative to the market benchmark over various periods.  High Beta values suggest higher volatility compared to the market.


**2. Recent Price Movement:**

* **Closing Price:** $99.65
* **5-day Moving Average:** $100.15
* **20-day Moving Average:** $99.61
* **60-day Moving Average:** $100.65

The price is slightly below the 5-day and 60-day moving averages, suggesting a short-term downtrend. The close proximity to the 20-day moving average indicates the price is near a potential support level.

**3. Technical Indicators and Expected Return:**

* **RSI:** 56.97 (Slightly above neutral; neither overbought nor oversold)
* **PPO:** 0.15 (Positive, suggesting upward momentum, though weak)
* **Relative Strength:**  The recent 20-day relative strength increase of +4.3% suggests short-term upward momentum.
* **Expected Return:** 38.1% (over the long-term, exceeding the S&P 500).  This high expected return needs to be viewed cautiously.  It's crucial to understand the assumptions behind this projection to evaluate its reliability. Given the historical underperformance relative to the S&P 500 (as indicated by the Alpha and the large gap in cumulative returns), a 38.1% excess return needs strong justification.


**4. Recent Earnings Analysis:**

The provided earnings data shows some inconsistencies (duplicate entry for 2024-11-06).  A clear trend in EPS and Revenue isn't immediately apparent from this limited data. Further analysis with more complete and consistent data is needed to draw meaningful conclusions.  We need to account for seasonality and potentially review financial statements for a deeper dive into revenue streams and profit drivers.

| Date       | EPS  | Revenue       |
|------------|------|----------------|
| 2024-11-06 | 1.25 | $16.66B        |
| 2024-08-05 | 2.15 | $16.11B        |
| 2024-05-03 | 1.88 | $15.78B        |
| 2023-11-03 | 1.87 | $15.96B        |


**5. Financial Information:**

The financial data reveals some important trends:

* **Revenue:** Revenue has remained relatively stable over the past few quarters, with minor fluctuations.
* **Profit Margin:** Profit margins are generally high and have slightly decreased over recent quarters.
* **Equity:** Equity has shown growth, though there's a dip in Q4 2023 that is concerning.
* **ROE (Return on Equity):** ROE shows variability.  The negative ROE in Q4 2023 is a major red flag. A more in-depth analysis is needed to understand the causes of this.

| Quarter    | Revenue     | Profit Margin | Equity (B) | ROE (%) |
|------------|-------------|---------------|------------|---------|
| 2024-09-30 | $16.66B     | 75.51%        | $44.50     | 7.09    |
| 2024-06-30 | $16.11B     | 76.76%        | $43.58     | 12.52   |
| 2024-03-31 | $15.78B     | 77.56%        | $40.36     | 11.80   |
| 2023-12-31 | $14.63B     | 73.26%        | $37.58     | -3.26   |
| 2023-09-30 | $15.96B     | 73.29%        | $41.25     | 11.50   |


**7. Overall Analysis:**

MRK's performance has lagged the S&P 500 significantly. While the expected long-term return is high, the negative Alpha and the substantial underperformance against the market benchmark need careful scrutiny.  The recent price action shows some instability, and while the RSI and PPO suggest some upward momentum, the negative ROE in Q4 2023 is alarming. A deeper dive into the financial statements is crucial to understand the reasons behind this negative ROE and the fluctuations in earnings. More consistent and complete earnings data is also needed for better analysis.  Before making any investment decisions, thorough due diligence is absolutely necessary.


**8. Disclaimer:** This report is for informational purposes only and does not constitute financial advice.  Investment decisions should be based on your own research and risk tolerance.
